Benefits
Hip bone density with salmon bone plus vitamin D3
In a two-year trial in 80 postmenopausal women with low bone mass, femoral neck density held steady (up 0.4 percent) on 2 g a day of salmon bone with 40 µg of added vitamin D3 and fell 2.4 percent on a placebo with no vitamin D. Because only one group got vitamin D, the result cannot be credited to salmon bone. It was a single maker-funded trial, and only 59 women finished.
Spine and forearm bone density
In the same trial, lumbar spine density fell less on the salmon bone and vitamin D3 capsules than on placebo, but the between-group difference was not statistically significant (p = 0.058). Forearm (distal radius) density did not differ. A post hoc analysis found more women gaining at least 1 percent at the spine on the capsules, an exploratory result.
Bone turnover markers in blood
The trial also measured P1NP, a marker of bone building, and beta CTX, a marker of bone breakdown. Neither differed between the salmon bone and placebo groups over two years. These blood markers do not show a bone benefit on their own, and here they did not change.
Calcium, phosphorus and collagen from one ingredient
Because it is ground bone, the powder supplies calcium and phosphorus in the same mineral form found in human bone, plus collagen. The trial dose of 2 g gave about 380 mg of calcium, roughly a third of the 1,000 to 1,200 mg adults need daily from food and supplements combined. Check the calcium per serving on the label.
Blood calcium after a dose compared with calcium carbonate
In a crossover study of 12 postmenopausal women run by the maker, blood calcium 24 hours after a 2 g dose rose 1.28 percent, while calcium carbonate gave no significant rise. No direct comparison between the two products was reported. In an independent study of salmon bone from another source, calcium absorption did not differ significantly from calcium carbonate.
Joint comfort: completed trial without published results
The maker ran a six-month placebo-controlled trial of 2 g a day in 98 adults with mild to moderate hip or knee joint wear, scored with the WOMAC questionnaire. It was completed in January 2024, but no results have been posted or published, so nothing is known about whether it helped joints.
Mechanism of action
Calcium and phosphorus as bone mineral
Bone mineral is mostly calcium hydroxyapatite, and salmon bone powder supplies it in that form. Hydroxyapatite dissolves in stomach acid to release calcium and phosphate. In a trial of another microcrystalline hydroxyapatite, it raised blood calcium less than calcium citrate or carbonate, raised phosphate more, and lowered bone turnover markers to a similar degree.
Collagen matrix carried with the mineral
The powder keeps the collagen that holds bone mineral in place; the maker describes it as mainly type II. The trial authors propose that matrix proteins and growth factors add to the calcium effect but did not measure them. A pooled analysis of a bovine bone preparation (ossein hydroxyapatite) found about 1 percent better bone density than calcium carbonate.
Added vitamin D3 in the trial formula
The capsules in the two-year trial delivered 40 µg (1,600 IU) of vitamin D3 a day, while the placebo had none. Vitamin D is needed to absorb calcium from the gut, so the trial cannot separate the effect of the salmon bone from that of the vitamin D. Women in the salmon bone group also started with higher vitamin D levels. The maker's specification for CalGo itself lists no vitamin D.
Clinical trials
Randomized, double-blind, placebo-controlled trial at three Norwegian sites; 2 g/day of CalGo as four capsules (about 380 mg calcium, 500 mg type II collagen and 40 µg vitamin D3) or 2 g maltodextrin placebo for 24 months; registered NCT05066477; funded by Hofseth BioCare with support from the Research Council of Norway SkatteFUNN scheme (project 330172); four of seven authors (Bjerknes, Standal, Currie, Framroze) are Hofseth BioCare employees (Bjerknes et al. 2025, Biomedicines)
80 women aged 50 to 80 (average about 62) with femoral neck bone density in the osteopenic range (T-score above -2.5 and at or below -1.0), 40 per group; the target of 112 was not reached, and 59 (29 CalGo, 30 placebo) completed the 24-month scans used in the primary analysis.
Primary outcome: femoral neck density rose 0.4 percent on CalGo and fell 2.4 percent on placebo, an adjusted difference of 0.019 g/cm² (95% CI 0.001 to 0.038; p = 0.044). Lumbar spine loss was smaller on CalGo but not significantly (p = 0.058), and distal radius density, P1NP, beta CTX and quality of life did not differ. Fractures were 5 on CalGo and 3 on placebo; the trial was not designed for fractures. Baseline vitamin D and lumbar spine density were higher in the CalGo group. Because only the CalGo capsules contained vitamin D3, the trial compares CalGo plus vitamin D with no supplement and cannot credit the hip result to salmon bone.
Randomized, double-blind crossover study in Mumbai, India; 2 g of CalGo (four 500 mg capsules) or 1 g of calcium carbonate, described by the authors as equal in elemental calcium, with a 7-day washout; serum calcium measured 24 hours after dosing and analyzed with paired one-tailed t-tests; all four authors are affiliated with Hofseth BioCare, and no funding statement or registry number is given; not indexed in PubMed (Currie et al. 2022, Biomed J Sci Tech Res)
12 postmenopausal women aged 55 to 75 (average 65).
Mean serum calcium rose from 9.36 to 9.48 mg/dL after CalGo (a 1.28 percent rise, p < 0.05) and from 9.31 to 9.33 mg/dL after calcium carbonate (not significant); all values stayed within the normal range. No direct statistical comparison between the two products was reported, and blood calcium is an indirect marker of absorption. Vitamin D (calcifediol) and creatinine did not change.
Randomized, triple-masked, three-arm parallel trial for 6 months: CalGo 2 g/day (ten capsules giving 340 mg calcium as microcrystalline hydroxyapatite and 40 µg vitamin D3), hydrolyzed type II collagen from salmon bone, or maltodextrin placebo; sponsored by Hofseth BioCare with Møre og Romsdal Hospital Trust; completed January 2024 (Lian et al. 2021, ClinicalTrials.gov NCT05070871)
98 adults aged 18 to 70 with mild to moderate hip or knee osteoarthritis (Kellgren-Lawrence grade 1 to 3); people with fish allergy were excluded.
The primary outcome was change in the WOMAC score at 3 and 6 months, with pain ratings and global assessment as secondary outcomes. As of the last registry update (February 2024) no results were posted, and no matching publication was found in PubMed or Europe PMC in November 2026, so no joint result can be reported.